We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) ended the recent trading session at $26.37, demonstrating a -3.79% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.81% for the day. Elsewhere, the Dow gained 0.73%, while the tech-heavy Nasdaq added 1.03%.
Heading into today, shares of the company had gained 34.14% over the past month, outpacing the Medical sector's loss of 0.96% and the S&P 500's gain of 9.47%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on May 11, 2026. The company is predicted to post an EPS of $0.04, indicating a 80% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $619.62 million, reflecting a 5.74% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.56 per share and revenue of $2.85 billion, which would represent changes of +5.66% and +21.29%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 16.52% higher within the past month. Hims & Hers Health, Inc. is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Hims & Hers Health, Inc. is currently exchanging hands at a Forward P/E ratio of 49.06. This represents a premium compared to its industry average Forward P/E of 24.88.
We can also see that HIMS currently has a PEG ratio of 2.82. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical Info Systems industry stood at 1.44 at the close of the market yesterday.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS - Free Report) ended the recent trading session at $26.37, demonstrating a -3.79% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.81% for the day. Elsewhere, the Dow gained 0.73%, while the tech-heavy Nasdaq added 1.03%.
Heading into today, shares of the company had gained 34.14% over the past month, outpacing the Medical sector's loss of 0.96% and the S&P 500's gain of 9.47%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company's earnings report is set to go public on May 11, 2026. The company is predicted to post an EPS of $0.04, indicating a 80% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $619.62 million, reflecting a 5.74% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $0.56 per share and revenue of $2.85 billion, which would represent changes of +5.66% and +21.29%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 16.52% higher within the past month. Hims & Hers Health, Inc. is currently a Zacks Rank #3 (Hold).
From a valuation perspective, Hims & Hers Health, Inc. is currently exchanging hands at a Forward P/E ratio of 49.06. This represents a premium compared to its industry average Forward P/E of 24.88.
We can also see that HIMS currently has a PEG ratio of 2.82. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical Info Systems industry stood at 1.44 at the close of the market yesterday.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 92, finds itself in the top 38% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.